Abstract: Inhaled budesonide and salbutamol represent the most important and frequently used drugs in asthmatic children during acute exacerbation. However, there is still no consensus about their resulting metabolic derangements; thus, this study was conducted to determine the distinct metabolic profiles of these two drugs. A total of 69 children with asthma during acute exacerbation were included, and their serum and urine were investigated using high-resolution nuclear magnetic resonance (NMR). A metabolomics analysis was performed using a principal component analysis and orthogonal signal correction-partial least squares using SIMCA-P. The different metabolites were identified, and the distinct metabolic profiles were analysed using MetPA. A high-resolution NMR-based serum and urine metabolomics approach was established to study the overall metabolic changes after inhaled budesonide and salbutamol in asthmatic children during acute exacerbation. The perturbed metabolites included 22 different metabolites in the serum and 21 metabolites in the urine. Based on an integrated analysis, the changed metabolites included the following: increased 4-hydroxybutyrate, lactate, cis-aconitate, 5-hydroxyindoleacetate, taurine, trans-4-hydroxy-l-proline, tiglylglycine, 3-hydroxybutyrate, 3-methylhistidine, glucose, cis-aconitate, 2-deoxyinosine and 2-aminoadipate; and decreased alanine, glycerol, arginine, glycylproline, 2-hydroxy-3-methylvalerate, creatine, citrulline, glutamate, asparagine, 2-hydroxyvalerate, citrate, homoserine, histamine, sn-glycero-3-phosphocholine, sarcosine, ornithine, creatinine, glycine, isoleucine and trimethylamine N-oxide. The MetPA analysis revealed seven involved metabolic pathways: arginine and proline metabolism; taurine and hypotaurine metabolism; glycine, serine and threonine metabolism; glyoxylate and dicarboxylate metabolism; methane metabolism; citrate cycle; and pyruvate metabolism. The perturbed metabolic profiles suggest potential metabolic reprogramming associated with a combination treatment of inhaled budesonide and salbutamol in asthmatic children.
Glucocorticoids and beta2 agonists represent the most important and frequently used drugs for symptom control in asthmatic children during acute exacerbation [1, 2] . Current guidelines recommend the combined use of glucocorticoids and beta2 agonists as the preferred therapy for asthmatic children during acute exacerbation [3, 4] . The glucocorticoid and beta2 agonist therapies are effective at controlling airway inflammation, reducing asthma symptoms, decreasing airway hyper-responsiveness and reducing the frequency and severity of exacerbations as well as asthma mortality. Despite their undoubted effectiveness and safety, there is still no consensus about the resulting metabolic derangements, including the development of dyslipidaemia, insulin resistance, glucose intolerance, diabetes, central adiposity and skeletal muscle wasting [5] [6] [7] .
Both glucocorticoids and beta2 agonists have the potential to influence glucose, lipid and protein metabolism [8] [9] [10] .
Budesonide is the most widely used glucocorticoid for the treatment of asthmatic diseases [11] . The metabolic effects of budesonide are mediated through its binding to the glucocorticoid receptor, which is ubiquitously expressed in the human body. Upon ligand binding, the glucocorticoid receptor translocates into the nucleus, where it enables the initiation or suppression of metabolism-related gene transcription [12] [13] [14] . Salbutamol is also widely used as a relatively selective b2-adrenergic bronchodilator for the relief of acute asthma symptoms [15] . However, it was reported that therapeutic doses exert adrenergic stimulatory effects and an anabolic-like effect, resulting in metabolism control [16] . To avoid side effects, the drugs were delivered through inhalation [17, 18] . However, inhaled drugs reach systemic circulation either by direct absorption through the lungs or via gastrointestinal absorption of the drug when it is inadvertently swallowed [19, 20] . It was reported that budesonide triggers several chronic impairment effects, such as oxidative stress, cellular transformation, tissue fibrillation and adrenal insufficiency [14, 21] . However, there have been no studies of the effects of inhaled budesonide or salbutamol on metabolic derangements. Nuclear magnetic resonance (NMR)-based metabolomics approaches are wellestablished for revealing the overall changes in metabolites in body fluids and are widely used to determine metabolic perturbations.
The present study employed high-resolution 1 H NMR-based metabolomics to reveal the metabolic profiles resulting from inhaled glucocorticoids and beta2 agonists. A total of 69 children with asthma during acute exacerbation were included, and markers in their serum and urine were measured using multivariate data analysis and metabolic pathway analyses. This study provides insight into the metabolic reprogramming in asthmatic children after inhaled budesonide and salbutamol.
Materials and Methods
Study design and subjects. A total of 69 inpatient children with asthma during acute exacerbation (35 boys and 34 girls) were recruited from the Department of Paediatrics of Shanghai Jiao Tong University Affiliated Sixth People Hospital. The inclusion criteria for the study were as follows: (1) patients 1-12 years old, (2) a clinical diagnosis of asthma with acute exacerbations, (3) no respiratory system infections for at least 1 month and (4) no use of any topical or systemic corticosteroid or beta2 agonist treatment within the previous 3 months. Each patient received inhaled budesonide (200-800 lg/day depending on disease severity and patient age) and salbutamol (5-10 mg/day) for at least five treatments. The inclusion criteria for the asthma control participants were the same as above but without the previous usage of any corticosteroids or beta2 agonists. This study was approved by the Ethics Committee of the Shanghai Jiao Tong University Affiliated Sixth People Hospital, and informed consent was obtained from a parent of each child prior to enrolment in the study.
Sample preparations for NMR spectroscopy. Between 8.00 and 11.00 a.m., 5 mL of midstream urine was collected in a urine tube, and 2 mL of venous blood was collected in a vacutainer tube. The urine samples were immediately stored at 4°C and then frozen at À80°C within 12 hr. The blood samples were kept at room temperature for 30 min. for clotting. The clotted blood samples were centrifuged at 3000 9 g at 4°C for 20 min. to collect the supernatant serum, which was quickly stored at À80°C until the high-resolution 1 H NMR experiment was performed. To obtain robust and reproducible data, all of the samples were prepared according to a previous protocol [22] . Briefly, the samples were thawed at 4°C for 2 hr and then left at room temperature for 1 hr. Then, 300 lL of thawed samples was mixed with 300 lL of phosphate buffer (pH 7.4) containing 10% D 2 O. After vortex mixing and centrifugation, 550 lL of the solution was transferred into 5-mm NMR tubes and kept at 4°C until the NMR analysis.
Measurement protocols of
1 H-NMR spectroscopy. All of the spectra were recorded using a Bruker AMX-600 NMR spectrometer operated at a 600.13 MHz 1 H resonance frequency with the TopSpin software package 3.0 (Bruker Biospin, Rheinstetten, Germany). Quality control tests were performed at the beginning of every measurement day. A representative sample was used for NMR probe tuning and matching, determination of the transmitter offset value for water pulse presaturation and 90 pulse adjustments. Each sample was locked and automatically shimmed; for all experiments, the receiver gain was set to 90.5 and the temperature was set to 310 K.
For the urine samples, a conventional pre-saturation 1 H-NOESY pulse sequence was employed for solvent suppression with an equation delay sequence of 90°-t 1 -90°-t m -90°-acquisition, where the relaxation delay was 2 sec., the t 1 delay was 4 lsec., and the mixing time tm was 100 msec. A total of 128 scans with a spectral width of 5 kHz were collected for all NMR spectra. All signals were zero-filled to 32 k before Fourier transformation (FT). For the serum samples, a CPMG (Carr-Purcell-Meiboom-Gill) pulse sequence was employed to obtain the low molecular signals with an equation delay of 90°-(t-180°-t) n -acquisition as in our previous study [10] . A total of 128 scans with a spectral width of 5 kHz were collected for all NMR spectra. All of the signals were zero-filled to 32 k before FT.
Metabolite identification and chemical signal assignment. Chenomx NMR Suite software 8.1 (Chenomx Inc., Edmonton, AB, Canada) was used for the identification of metabolites from 1 H NMR spectra of biological samples. Due to the overlap of the signals, two-dimensional J-resolved (jresgpprqf) spectra were collected to visualize scalar couplings and improve metabolite identification from small metabolites [23] . The experiment was performed using four transients per increment for a total of 32 increments, which were collected into 16 k data points using spectral widths of 6 kHz in F2 (chemical shift axis) and 40 Hz in F1 (spin-spin coupling constant axis). The data sets were zero-filled to 128 points in F1, and both dimensions were multiplied by sine-bell window functions prior to Fourier transformation. Spectra were tilted by 45°, symmetrized about F1 and calibrated (DSS, 0.0 ppm), and the proton-decoupled skyline projections (pJRES) were obtained using TopSpin software.
Data reduction of the NMR data. After the Fourier transformation, phase correction and baseline correction were carefully performed. Metabolomics analysis. The data set was analysed by pattern recognition methods using the software packages SIMCA-P 11.5 (Umetrics AB, Ume a, Sweden). To explain the maximum variation between the samples, a principal component analysis (PCA) bilinear decomposition method was used to view the clusters within the multivariate data. To eliminate the effect of intersubject variability amongst the participants and to determine the endogenous metabolites that significantly contributed to classification, orthogonal signal correction (OSC) was used to remove linear combinations of variable X that were orthogonal to the Y vector of the dependent variables and to describe maximum separation. Therefore, OSC was employed, and the orthogonal projections to latent structure (OPLS) method was applied for better classification. The cumulative values of R 2 Y and Q 2 Y close to 1 indicate an excellent model [23, 24] . The specific metabolites between classes were interpreted using variable importance in the projection (VIP) and correlation coefficients.
Metabolic pathway analysis. To identify the most relevant metabolic pathways affected by inhaled budesonide and salbutamol in asthmatic children, metabolic pathway analysis was employed for the pathway enrichment analysis and pathway topology analysis using MetPA 3.0 (www.metaboanalyst.ca). The pathway enrichment analysis used GlobalTest to analyse the concentration values with high sensitivity and to identify subtle changes involved in the same biological pathway [25] . Relative betweenness centrality was used for the metabolite importance measurement and the established global network topology analysis.
General statistical methods. After data collection, the data were checked manually for completeness and inconsistencies. The attribute data are expressed as counts and were analysed using the nonparametric cross-tab method. The measurement data are expressed as the means AE S.D. The differences between the two groups were analysed using Student's two-sided t-test. The level of significance was set at p < 0.05. All of the statistical analyses were performed using Origin software 8.1 (OriginLab Corp., Northhampton, MA, USA).
Results

Characteristics of patient groups.
The demographic and clinical data of all of the study participants are summarized in table 1. Sixty-nine children with asthma during acute exacerbation who were administered combined treatment with budesonide and salbutamol and 48 ageand sex-matched asthmatic children controls were included. The treatment group inhaled budesonide and salbutamol at least five times, with an average of 10.48 AE 3.63 times. During the study, a total of 37, 31 and 47 patients used procaterol, montelukast and antibiotics, respectively. The blood test results and biochemical responses of the two groups are listed in table 2. The biochemical responses were in the normal range, and there were no significant differences between the two groups.
Distinct metabolic perturbations in the serum samples. In a metabolomics study, the detection of global metabolic profiles is preferred to obtain a comprehensive understanding of the biological pathways. The NMR method detects low levels of molecular metabolites in complex biological samples due to its high reproducibility and robust statistics [22, 26] . Therefore, a 1 H NMR-based metabolomics approach was employed to reveal the metabolite alterations after the combination treatment with budesonide and salbutamol in asthmatic children. After the NMR spectra were acquired, the region from d 0.4 to 4.7 containing aliphatic metabolite signals was shown, and the obvious metabolites in the 1 H NMR spectra in serum were labelled and assigned ( fig. 1A) . Given the overlap of one-dimensional spectra, the splitting patterns and coupling constants of each signal could not be recognized. Thus, 2D experiments of J-resolved spectra were used to reveal the metabolites in the highly crowded regions by showing the coupling constants on the second axis ( fig. 1B) . The serum spectra contained numerous signals from the following small molecules: lactate, alanine, acetate, glutamate, creatine, taurine, 5-hydroxyindoleacetate (5-HIAA) and glucose.
Statistical evaluation by PCA showed clear separation between the control samples and combination treatment samples ( fig. 2A ). This result was highly encouraging given that the PCA was an unsupervised multi-dimensional statistical method, and thus, any clusters that are evident were likely to be due to natural differences in the metabolomics profiles. The wider spread of the combination treatment samples in PCA compared to the controls was caused by the different levels of metabolites as a manifestation of within-subject variations and/or variations based on the date of subsequent sampling. To relate the metabolites to the samples, the OPLS method was applied to discriminate the sample characteristics ( fig. 2B) . The model for the classification of the two groups obtained a satisfactory validation with R 2 X (cum) 0.920, R 2 Y (cum) 0.995 and Q 2 (cum) 0.993, respectively, to determine which metabolites were highly diagnostic for group separation. The derived S-plot ( fig. 3C ) was used to visually display the covariance and correlation between features. To elucidate the most reliable class discriminating variables, parameters of p1 and p1 (corr) were set as >AE0.05 [24] . Based on the directions of the loading plot that corresponded to the score plot, 22 metabolites satisfied the restrictive parameters, including increased levels of 4-hydroxybutyrate, lactate, cis-aconitate, 5-HIAA, taurine, trans-4-hydroxy-l-proline, tiglylglycine, 3-hydroxybutyrate, 3-methylhistidine and glucose and decreased levels of alanine, glycerol, arginine, glycylproline, 2-hydroxy-3-methylvalerate, creatine, citrulline, glutamate, asparagine, 2-hydroxyvalerate and citrate. These altered metabolites indicated that the combination treatment with budesonide and salbutamol alters the metabolite levels. To validate the correlation between these metabolites and grouped samples, a clustered heat map analysis was performed ( fig. 2D ).
Columns represent different samples from the combination treatment and control groups, whereas rows represent potential metabolites that are responsible for the discrimination. The shade of the greyscale indicates the fold change of the metabolites. Based on the heat map, the strong positive correlations between samples and the metabolites were obvious. The samples from the combination treatment and control groups showed clear differences based on the metabolic profiles of 22 metabolites. Additionally, based on the metabolomics analysis performed to determine the metabolic perturbations of signal treatment with either budesonide or salbutamol, there was no principal component with which to differentiate the two groups, and the PCA score plot showed no distinction between the combination treatment samples and the controls. After OSC, the PLS-DA and OPLS model also did not differentiate the samples and the controls. These findings indicated that either inhaled budesonide or salbutamol individually had no significant metabolic effect in asthmatic children during acute exacerbation. Moreover, the metabolic perturbations from procaterol, montelukast and antibiotics were analysed using a metabolomics approach, and we elucidated that they had little metabolic effect in asthmatic children.
Distinct metabolic perturbations in the urine samples.
Urine is the most commonly used biological fluid for metabolomics research because of its concentration of low-molecule metabolites. Some obvious differential signals between the control and combination treatment samples were directly observed in the spectra and are shown in fig. 3 . The unsupervised PCA method exhibited obvious classification between the control group and combination treatment groups ( fig. 4A) . However, the model parameters calculated from the first two principal components could only explain 34.1% of the variables. Therefore, the OSC-OPLS model was established as previously described. The score plot ( fig. 4B) showed the obvious separations of the two groups along the first two principal components with satisfactory predictive abilities (R 2 Y (cum) = 0.990, and Q 2 (cum) = 0.988).
Along with the changed levels of metabolites, the derived S-plot ( fig. 4C ) illustrates the major metabolite changes that resulted from the combination treatment including increased cis-aconitate, lactate, 2-deoxyinosine, 3-methylhistidine, 5-HIAA, 2-aminoadipate and glucose, as well as decreased citrulline, homoserine, histamine, alanine, asparagine, glycylproline, snglycero-3-phosphocholine, sarcosine, ornithine, creatine, creatinine, glycine, isoleucine and trimethylamine N-oxide. As described above, a clustered heat map analysis was performed to validate the correlation between these metabolites and the grouped samples ( fig. 4D ). The samples of the combination treatment and control groups were clearly separated based on the altered 21 metabolites. These data indicated that the combination treatment with budesonide and salbutamol regulates the metabolic profiles of asthmatic children. Interestingly, the metabolomics analysis to determine the metabolic perturbations of budesonide or salbutamol did not reveal any distinction between the samples and controls. This indicated that inhaled budesonide or salbutamol individually had no significant metabolic effect in asthmatic children, whereas the combination treatment regulated the metabolic profile of asthmatic children.
Distinct metabolic profiling of budesonide and salbutamol in asthmatic children during acute exacerbation.
The altered serum and urine metabolites were assessed in a combined and integrated analysis. A total of 36 metabolites were considered responsible for the combination treatment with budesonide and salbutamol in asthmatic children. All 36 attributed metabolites were analysed with MetPA, and the most influenced pathways are shown in fig. 5 ( Table S1 ). The most influenced metabolic pathway was ascribed a pathway impact of >0.1 and Àlog(p) > 20. Seven metabolic pathways were found to be reprogrammed: arginine and proline metabolism; taurine and hypotaurine metabolism; glycine, serine and threonine metabolism; glyoxylate and dicarboxylate metabolism; methane metabolism; citrate cycle; and pyruvate metabolism. The detailed metabolites are listed in Figure S1 -S7. These results prompted the reprogramming of the metabolic network influenced by budesonide and salbutamol treatment in children with asthma during acute exacerbation.
Discussion
In the present study, a high-resolution NMR-based serum and urine metabolomics approach was established to investigate the metabolic perturbations after inhalation of budesonide and salbutamol in children with asthma during acute exacerbation. A total of 36 metabolites involving seven metabolic pathways were found to be altered. Amongst the perturbed metabolism, arginine and proline metabolism was the most impacted pathway. We found that arginine, ornithine, citrulline, creatine, creatinine, hydroxyproline and sarcosine were also affected. This finding was consistent with previous studies that showed that cortisol regulates arginine and glutamine metabolism through a glucocorticoid receptor-mediated mechanism [27, 28] . Arginase was of particular importance for competing with nitric oxide synthesis. Increased arginase activity results in the production of nitric oxide in the bronchioles and potentiates airway reactivity [29] . Research findings have also suggested that in a murine asthma model, arginine treatment not only ameliorated the inflammatory airway response and attenuated the increases in arginase Fig. 2 . The serum PCA score plot (A), OSC-OPLS score plot (B), S-plot (C) and the heat map between the combination treatment and control groups. Score plots showing the degree of separation of the model between the control (red dots) and combination treatment (black triangles). Both models showed a strong regression (95%), but the targeted profiling data were well clustered with little differences within the subjects, except for an outlier that does not weaken classification (A, B) . The placed metabolites with p1 and p1 (corr) > AE0.05 were marked from the first component in the S-plots (C). expression but also elevated the nitric oxide levels by enhancing arginine bioavailability [30] . Arginine and its downstream products, such as ornithine, proline and hydroxyproline, were involved in collagen synthesis and cell proliferation during tissue remodelling. These findings indicate that the combination treatment with budesonide and salbutamol interacts with arginine metabolism to contribute to the improvement of asthmatic symptoms.
Combination treatment with inhaled budesonide and salbutamol also resulted in the regulation of glycine, serine and threonine metabolism. We also found that homoserine, glycine, creatine and sarcosine levels were changed when budesonide and salbutamol were inhaled in asthmatic children during acute exacerbation. Homoserine was metabolized from methionine and served as an intermediate for the biosynthesis of proteinogenic amino acids threonine and isoleucine. Serine was a precursor for the synthesis of membrane lipids, such as phospholipids and sphingolipids, and as a result, its demand increases during acute stress. Glycine is a non-essential amino acid that plays an essential role in metabolism homeostasis in patients with asthma [31] . Creatine interplays with glycine and serine and represents a major metabolic crossroad that links several biological pathways [32] .
The citrate cycle and pyruvate metabolism are the two main pathways associated with glucose homeostasis. Glucocorticoids regulate multiple aspects of glucose homeostasis by promoting gluconeogenesis in the liver and decreasing glucose uptake in skeletal muscle. Moreover, metabolic acidosis has also been reported during the treatment of asthma with the inhaled beta agonist, salbutamol [33] . In the present study, lactate, formic acid, acetate and citrate were also found to be changed after inhalation of budesonide and salbutamol in asthmatic children. Importantly, methane metabolism, taurine and hypotaurine metabolism, and glyoxylate and dicarboxylate metabolism were reprogrammed after the inhalation of budesonide and salbutamol in asthmatic children based on the pathway topology analysis.
Previous metabolomics studies revealed metabolic alteration in the asthma exacerbated condition [32, [34] [35] [36] . Histidine, trimethylamine N-oxide, phenylacetylglycine, threonine, 4-aminohippurate and methylamine were decreased, whereas creatine, glucose, hippurate, alanine, glycolate, succinate, myo-inositol, dimethylamine, formate, homovanillate, acetylcarnitine, taurine, lactate, oxaloacetate, cis-aconitate, 2-methylglutarate, tyrosine, 1-methylhistamine, 2-hydroxyisobutyrate, acetone, carnitine, 3-methyladipate and 2-oxoglutarate were increased in asthmatic children during acute exacerbation. However, there has been no systemic research on metabolic reprogramming resulting from the inhalation of budesonide and salbutamol in asthmatic children. Metabolites were the terminal products downstream from the proteins and genes. Thus, the involved metabolites reflect the related metabolic enzymes and genes that correlated with the combination treatment of glucocorticoids and beta2 agonists. Therefore, the variations in protein and gene expression require further investigation to illustrate the metabolic perturbations in asthmatic children. In our study, when we performed a metabolomics analysis to determine the metabolic perturbation of signal treatment of either budesonide or salbutamol, it was interesting that there was no distinction between the signal treatment group and the controls. These indicated that the inhalation of budesonide or salbutamol individually had no significant metabolic effect in asthmatic children during acute exacerbation, whereas the combination treatment regulated the metabolic profile. Furthermore, the metabolomics analysis of procaterol, montelukast and antibiotic treatment also revealed they had little metabolic effect in asthmatic children.
Notably, growing evidence suggests that metabolic derangement leads to airway dysfunction through the underlying mechanism of epithelial damage and airway smooth muscle proliferation [37] . Moreover, it was reported that metabolic derangement is a high risk factor for insulin resistance, metabolic syndrome, diabetes and childhood obesity [38] . Other studies found that children with a high body mass index had an increased risk of asthma [39] . However, a recent population-based study showed that asthmatic children experience higher rates of insulin resistance than those without asthma [40] . Conversely, children with asthma during acute exacerbation were often prescribed glucocorticoids and beta2 agonists. Although corticosteroids and beta2 agonists were inhaled and were effective in the bronchioles, the metabolic effect should not be neglected [6, 41] .
Collectively, a high-resolution NMR-based serum and urine metabolomics approach was established and used to study the overall metabolic changes after inhalation of budesonide and salbutamol in asthmatic children during acute exacerbation. The perturbed metabolic profiles included 22 metabolites in the serum and 21 metabolites in the urine. Integrated analysis confirmed that the changed metabolites included the following: increases in 4-hydroxybutyrate, lactate, cis-aconitate, 5-HIAA, taurine, trans-4-hydroxy-l-proline, tiglylglycine, 3-hydroxybutyrate, 3-methylhistidine, glucose, cis-aconitate, 2-deoxyinosine and 2-aminoadipate; and decreases in alanine, glycerol, arginine, glycylproline, 2-hydroxy-3-methylvalerate, creatine, citrulline, glutamate, asparagine, 2-hydroxyvalerate, citrate, homoserine, histamine, sn-glycero-3-phosphocholine, sarcosine, ornithine, creatinine, glycine, isoleucine and trimethylamine Noxide. The metabolic pathway analysis revealed seven involved metabolic pathways. The metabolic pathways suggested potential metabolic reprogramming associated with the combination treatment. Therefore, our findings may contribute to the in-depth understanding of metabolic regulation of budesonide and salbutamol in asthmatic children at the molecular level.
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